New research claims Reboxetine is useless

Reboxetine - sold as Edronax by Pfizer - is no more effective at countering major depression than a placebo. Researchers from the German Institute for Quality and Efficiency in Health Care reviewed trials of the drug and found that the risk of taking it far outweighed the benefits. The researchers found that three-quarters of the studies into the effectiveness of the drug - essentially the ones which showed it to be useless - were not published leading them to question the current National Institute for Health and Clinical Excellence (NICE) guidelines on its use in the U.K. which claim that "reboxetine is superior to placebo and as effective as other antidepressants."